Skip to main content

ALTRIA GROUP, INC.

For the period ended Jan 28, 2026. Filed Jan 29, 2026.

View on SEC.gov

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Jan 28, 2026 · Filed Jan 29, 2026

Use the contents to explore the available documents and sections.

MO$76.12-1.9%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

EX-99.1 · Forward-Looking and Cautionary Statements

Forward-Looking and Cautionary Statements

This release contains projections of future results and other forward-looking statements that are subject to a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

Important factors that could cause actual results to differ materially from those contained in the forward-looking statements included in this release are described in our publicly filed reports, including our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. These factors and risks include the following:

our inability to anticipate and respond to changes in adult nicotine consumer preferences and purchase behavior;

our inability to compete effectively;

the growth of the e-vapor category, including illicit disposable e-vapor products, which contributes to reductions in domestic cigarette consumption levels and shipment volume;

the impact of illicit trade in nicotine products and the sale of products designed to avoid the regulatory framework for nicotine products, each of which contribute to reductions in the consumption levels and shipment volumes of our businesses’ products;

our failure to develop and commercialize innovative products, including nicotine products that may reduce health risks relative to other nicotine products and appeal to adult nicotine consumers;

changes, including in macroeconomic and geopolitical conditions (including inflation and tariffs), that result in shifts in ANC disposable income and purchasing behavior, including choosing lower-priced and discount brands or products, and reductions in shipment volumes;

unfavorable outcomes with respect to litigation proceedings or any governmental investigations, including significant monetary and non-monetary remedies and importation bans;

the risks associated with significant federal, state and local government actions, including FDA regulatory actions and inaction, and various private sector actions;

the risk that regulators, including the FDA, and courts may interpret laws, rules and regulations applicable to our operating companies’ products differently than we do;

increases in nicotine product-related taxes;

our failure to complete or manage successfully strategic relationships or transactions, including acquisitions, dispositions, joint ventures, commercial relationships and investments in third parties, or realize the anticipated benefits of such transactions;

significant changes in price, availability or quality of tobacco, other raw materials or component parts, including as a result of changes in macroeconomic, climate and geopolitical conditions;

our reliance on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers and the risks associated with an extended disruption at a facility or in service by a supplier, distributor or distribution chain service provider;

the risk that we may be required to write down goodwill and intangible assets, including trademarks and other intellectual property, due to impairment;

the risks associated with our Initiative, including risks relating to business continuity, our internal control over financial reporting and audit procedures and our ability to recognize the expected efficiencies;

the risk that we could decide, or be required, to recall products;

the various risks related to health epidemics and pandemics and the measures that international, federal, state and local governments, agencies, law enforcement and health authorities implement to address them;

our inability to attract and retain a highly skilled workforce due to the decreasing social acceptance of tobacco usage, tobacco control actions and other factors;

the risks associated with the various U.S. and foreign laws and regulations to which we are subject due to our international business operations;

the risks concerning a challenge to our tax positions, an increase in the income tax rate or other changes to federal or state tax laws;

the risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters;

disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets;

a downgrade or potential downgrade of our credit ratings;

the impact of heightened focus by investors and other stakeholders on our performance relating to corporate responsibility matters;

the failure of our, or our key service providers’ or key suppliers’, information systems to function as intended, or cyber-attacks or security breaches affecting us or our key service providers or key suppliers;

our failure, or the failure of our key service providers or key suppliers, to comply with laws related to personal data protection, privacy, artificial intelligence and information security;

the risk that the expected benefits of our investment in ABI may not materialize in the expected manner or timeframe or at all; and

the risks associated with our investment in Cronos, including legal, regulatory and reputational risks and the risk that the expected benefits of the transaction may not materialize in the expected manner or timeframe or at all.

You should understand that it is not possible to predict or identify all factors and risks. Consequently, you should not consider the foregoing list to be complete. We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law. All subsequent written and oral forward-looking statements attributable to Altria or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

Source: Altria Group, Inc.Altria Client ServicesAltria Client Services
Mac Livingston, Vice President of Investor RelationsInvestor RelationsMedia Relations
Richard.M.Livingston@altria.com804-484-8222804-484-8897
www.altria.com/contact-us/media

ALTRIA GROUP, INC.

and Subsidiaries

Consolidated Statements of Earnings

For the Quarters Ended December 31,

(dollars in millions, except per share data)

(Unaudited)

20252024% Change
Net revenues$5,846$5,974(2.1)%
Cost of sales 11,4481,502
Excise taxes on products 1767868
Gross profit3,6313,6040.7%
Marketing, administration and research costs618601
Asset impairment and exit costs97535
Impairment of goodwill285—
Operating companies income1,7532,968(40.9)%
Amortization of intangibles2037
General corporate expenses8249
Operating income1,6512,882(42.7)%
Interest and other debt expense, net264255
Net periodic benefit income, excluding service cost(14)(28)
(Income) losses from investments in equity securities 1(112)(122)
Earnings before income taxes1,5132,777(45.5)%
Provision (benefit) for income taxes396(262)
Net earnings$1,117$3,039(63.2)%
Per share data:
Diluted earnings per share$0.66$1.79(63.1)%
Weighted-average diluted shares outstanding1,6771,694(1.0)%
1 Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5.
ALTRIA GROUP, INC.
and Subsidiaries
Selected Financial Data
For the Quarters Ended December 31,
(dollars in millions)
(Unaudited)
Net Revenues
Smokeable Products · Oral Tobacco Products · E-Vapor Products · All Other · Total
2025$5,119$706$21$—$5,846
20245,26369222(3)5,974
% Change(2.7)%2.0%(4.5)%100.0%(2.1)%
Reconciliation:
For the quarter ended December 31, 2024$5,263$692$22$(3)$5,974
Acquisition and disposition-related items - 2025——19—19
Operations(144)14(20)3(147)
For the quarter ended December 31, 2025$5,119$706$21$—$5,846
Operating Companies Income (Loss)
Smokeable Products · Oral Tobacco Products · E-Vapor Products · All Other · Total
2025$2,643$438$(1,259)$(69)$1,753
20242,638453(58)(65)2,968
% Change0.2%(3.3)%(100%+)(6.2)%(40.9)%
Reconciliation:
For the quarter ended December 31, 2024$2,638$453$(58)$(65)$2,968
Asset impairment, exit and implementation costs - 2024608——68
Tobacco and health and certain other litigation items - 202411———11
718——79
NPM Adjustment Items - 202522———22
Acquisition and disposition-related items - 2025——19—19
Asset impairment, exit and implementation costs - 2025(11)(2)(1,255)—(1,268)
Tobacco and health and certain other litigation items - 2025(11)———(11)
—(2)(1,236)—(1,238)
Operations(66)(21)35(4)(56)
For the quarter ended December 31, 2025$2,643$438$(1,259)$(69)$1,753
ALTRIA GROUP, INC.
and Subsidiaries
Consolidated Statements of Earnings
For the Years Ended December 31,
(dollars in millions, except per share data)
(Unaudited)
20252024% Change
Net revenues$23,279$24,018(3.1)%
Cost of sales 15,5976,077
Excise taxes on products 13,1403,574
Gross profit14,54214,3671.2%
Marketing, administration and research costs2,1202,122
Asset impairment and exit costs978389
Impairment of goodwill1,158—
Operating companies income10,28611,856(13.2)%
Amortization of intangibles132139
General corporate expenses255476
Operating income9,89911,241(11.9)%
Interest and other debt expense, net1,0791,037
Net periodic benefit income, excluding service cost(59)(102)
(Income) losses from investments in equity securities 1(510)(652)
Gain on the sale of IQOS System commercialization rights—(2,700)
Earnings before income taxes9,38913,658(31.3)%
Provision for income taxes2,4422,394
Net earnings$6,947$11,264(38.3)%
Per share data2:
Diluted earnings per share$4.12$6.54(37.0)%
Weighted-average diluted shares outstanding1,6831,718(2.0)%
1 Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5.
2 Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.
ALTRIA GROUP, INC.
and Subsidiaries
Selected Financial Data
For the Years Ended December 31,
(dollars in millions)
(Unaudited)
Net Revenues
Smokeable Products · Oral Tobacco Products · E-Vapor Products · All Other · Total
2025$20,485$2,802$(13)$5$23,279
202421,2042,77640(2)24,018
% Change(3.4)%0.9%(100%+)100%+(3.1)%
Reconciliation:
For the year ended December 31, 2024$21,204$2,776$40$(2)$24,018
Acquisition and disposition-related items - 2025——(23)—(23)
Operations(719)26(30)7(716)
For the year ended December 31, 2025$20,485$2,802$(13)$5$23,279
Operating Companies Income (Loss)
Smokeable Products · Oral Tobacco Products · E-Vapor Products · All Other · Total
2025$10,984$1,828$(2,297)$(229)$10,286
202410,8211,449(171)(243)11,856
% Change1.5%26.2%(100%+)(5.8)%(13.2)%
Reconciliation:
For the year ended December 31, 2024$10,821$1,449$(171)$(243)$11,856
NPM Adjustment Items - 2024(29)———(29)
Asset impairment, exit and implementation costs - 202460362——422
Tobacco and health and certain other litigation items - 202470———70
101362——463
NPM Adjustment Items - 202524———24
Acquisition and disposition-related items - 2025——(67)—(67)
Asset impairment, exit and implementation costs - 2025(49)(7)(2,128)—(2,184)
Tobacco and health and certain other litigation items - 2025(55)———(55)
(80)(7)(2,195)—(2,282)
Operations142246914249
For the year ended December 31, 2025$10,984$1,828$(2,297)$(229)$10,286
Schedule 5
ALTRIA GROUP, INC.
and Subsidiaries
Supplemental Financial Data
(dollars in millions)
(Unaudited)
For the Quarters Ended December 31,For the Years Ended December 31,
2025202420252024
The segment detail of excise taxes on products sold is as follows:
Smokeable products$743$839$3,042$3,469
Oral tobacco products242998105
$767$868$3,140$3,574
The segment detail of charges for resolution expenses related to state settlement agreements included in cost of sales is as follows:
Smokeable products$750$806$3,028$3,460
Oral tobacco products———8
$750$806$3,028$3,468
The segment detail of FDA user fees included in cost of sales is as follows:
Smokeable products$61$59$245$249
Oral tobacco products1155
$62$60$250$254
The detail of (income) losses from investments in equity securities is as follows:
ABI$(102)$(118)$(498)$(673)
Cronos(10)(4)(12)21
$(112)$(122)$(510)$(652)
ALTRIA GROUP, INC.
and Subsidiaries
Net Earnings and Diluted Earnings Per Share
For the Quarters Ended December 31,
(dollars in millions, except per share data)
(Unaudited)
Net EarningsDiluted EPS
2025 Net Earnings$1,117$0.66
2024 Net Earnings$3,039$1.79
% Change(63.2)%(63.1)%
Reconciliation:
2024 Net Earnings$3,039$1.79
2024 Acquisition and disposition-related items(13)—
2024 Asset impairment, exit and implementation costs510.03
2024 Tobacco and health and certain other litigation items8—
2024 Amortization of intangibles300.01
2024 ABI-related special items320.02
2024 Cronos-related special items(5)—
2024 Income tax items(928)(0.55)
Subtotal 2024 special items 1(825)(0.49)
2025 NPM Adjustment Items130.01
2025 Acquisition and disposition-related items140.01
2025 Asset impairment, exit and implementation costs(1,015)(0.61)
2025 Tobacco and health and certain other litigation items(7)—
2025 Amortization of intangibles(18)(0.01)
2025 ABI-related special items(47)(0.03)
2025 Cronos-related special items7—
2025 Income tax items(12)(0.01)
Subtotal 2025 special items(1,065)(0.64)
Fewer shares outstanding—0.01
Change in tax rate380.02
Operations(70)(0.03)
2025 Net Earnings$1,117$0.66
1 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures.
ALTRIA GROUP, INC.
and Subsidiaries
Reconciliation of GAAP and non-GAAP Measures
For the Quarters Ended December 31,
(dollars in millions, except per share data)
(Unaudited)
Earnings before Income Taxes · Provision (benefit) for Income Taxes · Net Earnings · Diluted EPS
2025 Reported$1,513$396$1,117$0.66
NPM Adjustment Items(18)(5)(13)(0.01)
Acquisition and disposition-related items(20)(6)(14)(0.01)
Asset impairment, exit and implementation costs1,2682531,0150.61
Tobacco and health and certain other litigation items1037—
Amortization of intangibles202180.01
ABI-related special items5912470.03
Cronos-related special items(7)—(7)—
Income tax items—(12)120.01
2025 Adjusted for Special Items$2,825$643$2,182$1.30
2024 Reported$2,777$(262)$3,039$1.79
Acquisition and disposition-related items(14)(1)(13)—
Asset impairment, exit and implementation costs6817510.03
Tobacco and health and certain other litigation items1138—
Amortization of intangibles377300.01
ABI-related special items419320.02
Cronos-related special items(4)1(5)—
Income tax items—928(928)(0.55)
2024 Adjusted for Special Items 1$2,916$702$2,214$1.30
2025 Reported Net Earnings and Reported Diluted EPS$1,117$0.66
2024 Reported Net Earnings and Reported Diluted EPS$3,039$1.79
% Change(63.2)%(63.1)%
2025 Adjusted Net Earnings and Adjusted Diluted EPS$2,182$1.30
2024 Adjusted Net Earnings and Adjusted Diluted EPS$2,214$1.30
% Change(1.4)%—%
1 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures.
ALTRIA GROUP, INC.
and Subsidiaries
Net Earnings and Diluted Earnings Per Share
For the Years Ended December 31,
(dollars in millions, except per share data)
(Unaudited)
Net EarningsDiluted EPS1
2025 Net Earnings$6,947$4.12
2024 Net Earnings11,264$6.54
% Change(38.3)%(37.0)%
Reconciliation:
2024 Net Earnings$11,264$6.54
2024 NPM Adjustment Items(20)(0.01)
2024 Acquisition and disposition-related items(1,862)(1.08)
2024 Asset impairment, exit and implementation costs3150.18
2024 Tobacco and health and certain other litigation items760.04
2024 Amortization of intangibles1150.07
2024 ABI-related special items2—
2024 Cronos-related special items150.01
2024 Income tax items(969)(0.56)
Subtotal 2024 special items2(2,328)(1.35)
2025 NPM Adjustment Items150.01
2025 Acquisition and disposition-related items(66)(0.04)
2025 Asset impairment, exit and implementation costs(1,921)(1.14)
2025 Tobacco and health and certain other litigation items(44)(0.03)
2025 Amortization of intangibles(110)(0.06)
2025 ABI-related special items(75)(0.04)
2025 Cronos-related special items5—
2025 Income tax items(5)—
Subtotal 2025 special items(2,201)(1.30)
Fewer shares outstanding—0.11
Change in tax rate1190.07
Operations930.05
2025 Net Earnings$6,947$4.12
1 Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.
2 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures.

each period.

ALTRIA GROUP, INC.
and Subsidiaries
Reconciliation of GAAP and non-GAAP Measures
For the Years Ended December 31,
(dollars in millions, except per share data)
(Unaudited)
Earnings before Income Taxes · Provision for Income Taxes · Net Earnings · Diluted EPS1
2025 Reported$9,389$2,442$6,947$4.12
NPM Adjustment Items(20)(5)(15)(0.01)
Acquisition and disposition-related items7610660.04
Asset impairment, exit and implementation costs2,1842631,9211.14
Tobacco and health and certain other litigation items5814440.03
Amortization of intangibles132221100.06
ABI-related special items9520750.04
Cronos-related special items(5)—(5)—
Income tax items—(5)5—
2025 Adjusted for Special Items$11,909$2,761$9,148$5.42
2024 Reported13,6582,39411,2646.54
NPM Adjustment Items(27)(7)(20)(0.01)
Acquisition and disposition-related items(2,527)(665)(1,862)(1.08)
Asset impairment, exit and implementation costs4221073150.18
Tobacco and health and certain other litigation items10125760.04
Amortization of intangibles139241150.07
ABI-related special items2—2—
Cronos-related special items183150.01
Income tax items—969(969)(0.56)
2024 Adjusted for Special Items2$11,786$2,850$8,936$5.19
2025 Reported Net Earnings and Reported Diluted EPS$6,947$4.12
2024 Reported Net Earnings and Reported Diluted EPS$11,264$6.54
% Change(38.3)%(37.0)%
2025 Adjusted Net Earnings and Adjusted Diluted EPS$9,148$5.42
2024 Adjusted Net Earnings and Adjusted Diluted EPS$8,936$5.19
% Change2.4%4.4%
1 Diluted earnings per share are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.
2 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures.
ALTRIA GROUP, INC.
and Subsidiaries
Condensed Consolidated Balance Sheets
(dollars in millions)
(Unaudited)
December 31, 2025December 31, 2024
Assets
Cash and cash equivalents$4,474$3,127
Inventories1,0701,080
Other current assets388306
Property, plant and equipment, net1,7101,617
Goodwill and other intangible assets, net17,66319,918
Investments in equity securities8,6178,195
Other long-term assets1,095934
Total assets$35,017$35,177
Liabilities and Stockholders’ Equity (Deficit)
Current portion of long-term debt$1,569$1,527
Accrued settlement charges2,1782,354
Other current liabilities5,4074,900
Long-term debt24,14023,399
Deferred income taxes3,3703,749
Accrued pension costs122136
Accrued postretirement health care costs939935
Other long-term liabilities744365
Total liabilities38,46937,365
Total stockholders’ equity (deficit) attributable to Altria(3,502)(2,238)
Noncontrolling interest5050
Total liabilities and stockholders’ equity (deficit)$35,017$35,177
Total debt$25,709$24,926
ALTRIA GROUP, INC.
and Subsidiaries
Supplemental Financial Data for Special Items
For the Quarters Ended December 31,
(dollars in millions)
(Unaudited)
Net RevenuesCost ofSalesMarketing, administration and research costsImpairment of goodwillAmortization of intangiblesAsset impairment and exit costsGeneralcorporateexpensesInterest and other debt (income) expense, net(Income) losses from investments in equity securities
2025 Special Items - (Income) Expense
NPM Adjustment Items$—$(22)$—$—$—$—$—$4$—
Acquisition and disposition-related items(19)—————(1)——
Asset impairment, exit and implementation costs——8285—975———
Tobacco and health and certain other litigation items——11————(1)—
Amortization of intangibles————20————
ABI-related special items————————59
Cronos-related special items————————(7)
Acquisition and disposition-related items——————(14)——
Asset impairment, exit and implementation costs——33——35———
Tobacco and health and certain other litigation items——11——————
Amortization of intangibles————37————
ABI-related special items————————41
Cronos-related special items————————(4)

Note: This schedule is intended to provide supplemental financial data for certain income and expense items that management believes are not part of underlying operations and their presentation in Altria’s consolidated statements of earnings. This schedule is not intended to provide, or reconcile, non-GAAP financial measures.

1 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures.

ALTRIA GROUP, INC.
and Subsidiaries
Supplemental Financial Data for Special Items
For the Years Ended December 31,
(dollars in millions)
(Unaudited)
Net RevenuesCost ofSalesMarketing, administration and research costsAmortization of intangiblesAsset impairment and exit costsImpairment of goodwillGeneral corporate expensesInterest and other debt (income) expense, net(Income) losses from investments in equity securitiesGain on the sale of IQOS System commerciali-zation rights
2025 Special Items - (Income) Expense
NPM Adjustment Items$—$(24)$—$—$—$—$—$4$—$—
Acquisition and disposition-related items2344————9———
Asset impairment, exit and implementation costs——48—9781,158————
Tobacco and health and certain other litigation items——55————3——
Amortization of intangibles———132——————
ABI-related special items——————(1)—96—
Cronos-related special items————————(5)—
NPM Adjustment Items$—$(29)$—$—$—$—$—$2$—$—
Acquisition and disposition-related items——————173——(2,700)
Asset impairment, exit and implementation costs——33—389—————
Tobacco and health and certain other litigation items——70———301——
Amortization of intangibles———139——————
ABI-related special items——————593(60)—
Cronos-related special items————————18—

Note: This schedule is intended to provide supplemental financial data for certain income and expense items that management believes are not part of underlying operations and their presentation in Altria’s consolidated statements of earnings. This schedule is not intended to provide, or reconcile, non-GAAP financial measures.

1 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures.

ALTRIA GROUP, INC.
and Subsidiaries
Supplemental Retail Share Data
(Unaudited)
Retail share results for oral tobacco products are based on data from Circana, a tracking service that uses a sample of stores to project market share and depict share trends. In the fourth quarter of 2025, Circana refreshed its retail scan data to account for a retailer data revision that impacted on! and total oral tobacco products retail share data for the second and third quarters of 2025. It is the standard practice of retail services to periodically refresh their retail scan services, which could restate retail share results that were previously released in these services. This update impacted previously reported retail share performance for on! and total oral tobacco products. Restated share results are summarized below.
Retail Share (percent)
For the Three Months Ended
9/30/20256/30/2025
on!8.38.4
Total oral tobacco products30.9%32.9%
Retail Share (percent)
For the Nine Months EndedFor the Six Months Ended
9/30/20256/30/2025
on!8.48.5
Total oral tobacco products32.8%33.8%
Schedule 14
ALTRIA GROUP, INC.
and Subsidiaries
Calculation of Total Debt to Consolidated EBITDA and Net Debt to Consolidated EBITDA Ratios
For the Twelve Months Ended December 31, 2025 1
(dollars in millions)
(Unaudited)
Total
Consolidated Net Earnings$6,947
Interest and other debt expense, net1,079
Provision for income taxes2,442
Depreciation and amortization266
EBITDA 210,734
(Income) loss from investments in equity securities and noncontrolling interest, net(510)
Dividends from less than 50% owned affiliates208
Fair value adjustment for NJOY Transaction contingent payments25
Impairment of goodwill1,158
Asset impairment and exit costs978
Consolidated EBITDA 3$12,593
Current portion of long-term debt$1,569
Long-term debt24,140
Total Debt 425,709
Cash and cash equivalents 54,474
Net Debt 6$21,235
Ratios:
Total Debt / Consolidated Net Earnings3.7
Total Debt / Consolidated EBITDA2.0
Net Debt / Consolidated EBITDA1.7
1 Calculated as of the end of the applicable quarter on a rolling four quarters basis.
2 Reflects earnings before interest, taxes, depreciation and amortization (“EBITDA”).
3 Reflects the term “Consolidated EBITDA” as defined in Altria’s revolving credit agreement.
4 Reflects total debt as presented on Altria’s Consolidated Balance Sheet at December 31, 2025. See Schedule 10.
5 Reflects cash and cash equivalents as presented on Altria’s Consolidated Balance Sheet at December 31, 2025. See Schedule 10.
6 Reflects total debt, less cash and cash equivalents at December 31, 2025.
Schedule 15
ALTRIA GROUP, INC.
and Subsidiaries
Reconciliation of Reported OCI to Adjusted OCI
For the Year Ended December 31, 2025
(dollars in millions)
(Unaudited)
Smokeable ProductsOral Tobacco ProductsE-Vapor ProductsAll OtherTotal
Net revenues$20,485$2,802$(13)$5$23,279
Excise taxes(3,042)(98)——(3,140)
Revenues net of excise taxes$17,443$2,704$(13)$5$20,139
Reported operating companies income (OCI)$10,984$1,828$(2,297)$(229)$10,286
NPM Adjustment Items(24)———(24)
Acquisition and disposition-related items——67—67
Asset impairment, exit and implementation costs4972,128—2,184
Tobacco and health and certain other litigation items55———55
Adjusted OCI$11,064$1,835$(102)$(229)$12,568
Reported OCI margins 163.0%67.6%(100%+)(100%+)51.1%
Adjusted OCI margins 163.4%67.9%(100%+)(100%+)62.4%
Schedule 16
ALTRIA GROUP, INC.
and Subsidiaries
Reconciliation of Reported Diluted EPS to Adjusted Diluted EPS
For the Years Ended December 31, 2025 and 2022
(Unaudited)
For the Years Ended December 31, · Compounded Annual Growth Rate
2025 · 2022
Reported diluted EPS$4.12$3.198.9%
NPM Adjustment Items(0.01)(0.03)
Acquisition and disposition-related items0.04—
Asset impairment, exit and implementation costs1.14—
Tobacco and health and certain other litigation items0.030.05
Amortization of intangibles 10.060.03
JUUL changes in fair value—0.81
ABI-related special items0.041.12
Cronos-related special items—0.10
Income tax items—(0.40)
Adjusted diluted EPS$5.42$4.873.6%

1 Prior period amounts have been recast to conform with current period presentation for amortization of intangibles that were not previously identified as special items and that are now excluded from Altria’s adjusted financial measures.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.